The chances of hepatic resection curing hepatocellular carcinoma
Alessandro Cucchetti(Ospedale G.B. Morgagni - L.Pierantoni), Philip J. Johnson(Prince of Wales Hospital), Hidenori Toyoda(Ogaki Municipal Hospital), Matteo Cescon(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Masatoshi Kudo(Kindai University), Charing C. N. Chong(National University of Singapore), Takashi Kumada(Gifu Kyoritsu University), Jian‐Hong Zhong(Tumor Hospital of Guangxi Medical University), Antonio Daniele Pinna(Cleveland Clinic), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Toshifumi Tada(Himeji Red Cross Hospital), Bang‐De Xiang(Ministry of Education of the People's Republic of China), Keqing Shi(Wenzhou Medical University), Sarah Berhane(University Hospitals Birmingham NHS Foundation Trust), Paul B.S. Lai(Chinese University of Hong Kong), Le‐Qun Li(Shanghai Sixth People's Hospital), Giorgio Ercolani
Cited by 74
Related Papers
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k